Sugi Predict

Sugi Predict / Compounds / SCHEMBL8302890

SCHEMBL8302890

SCHEMBL8302890

O=C1CCC(c2ccc(Cl)cc2)=NN1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.68
▸ KCNH2 Q12809 1/20 0.58
▸ MAPT P10636 3/20 0.55
▸ LMNA P02545 2/20 0.55
▸ NPY1R P25929 1/20 0.55
▸ NPY2R P49146 1/20 0.55
▸ PDE3B Q13370 12/20 0.54
▸ PDE3A Q14432 12/20 0.54
▸ PDE4A P27815 5/20 0.54
▸ PDE4B Q07343 5/20 0.54
▸ PDE4C Q08493 5/20 0.54
▸ PDE4D Q08499 5/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ CYP3A4 P08684 1/20 0.54
▸ CYP2D6 P10635 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ KMT2A Q03164 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10353452 0.90 SMN1; SMN2 (0.81) SMN1; SMN2KCNH2MAPTLMNANPY1R
SCHEMBL9687996 0.83 SMN1; SMN2 (0.70) SMN1; SMN2KCNH2MAPTLMNANPY1R
SCHEMBL927560 0.83 SMN1; SMN2 (0.70) SMN1; SMN2KCNH2MAPTLMNANPY1R
SCHEMBL5561143 0.83 AXL (0.67) SMN1; SMN2KCNH2MAPTLMNAPDE3B
SCHEMBL20703136 0.82 PDE3B (0.52) SMN1; SMN2PDE3BPDE3APDE4APDE4B
SCHEMBL11718960 0.81 SMN1; SMN2 (0.58) SMN1; SMN2KCNH2MAPTLMNANPY1R
SCHEMBL6331085 0.81 SMN1; SMN2 (0.68) SMN1; SMN2KCNH2MAPTLMNANPY1R
SCHEMBL2846257 0.81 SMN1; SMN2 (0.68) SMN1; SMN2KCNH2MAPTLMNANPY1R
SCHEMBL7273533 0.81 SMN1; SMN2 (0.68) SMN1; SMN2KCNH2MAPTLMNANPY1R
SCHEMBL10556720 0.81 SMN1; SMN2 (0.68) SMN1; SMN2KCNH2MAPTLMNANPY1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240182452-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2024-06-06 — — US disclosed
US-11897867-B2 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer BAYER AKTIENGESELLSCHAFT (DE) 2024-02-13 — — US disclosed
EP-3661917-B1 6-((3-TRIFLUOROMETHYL)PHENYL)-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AG (DE) 2022-05-11 — — EP disclosed
US-20200247783-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2020-08-06 — — US disclosed
EP-3661917-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER Bayer Aktiengesellschaft (DE) 2020-06-10 — — EP disclosed
EP-2970145-B1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER BROAD INST INC (US) 2020-05-06 — — EP disclosed
WO-2019025554-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2019-02-07 — — WO disclosed
EP-0478195-B1 Dihydropyridazinones and pyridazinones as fungicides ROHM & HAAS (US) 1999-05-26 — — EP disclosed
US-5883090-A Endothelin receptor antagonists MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-03-16 — — US disclosed
US-5753642-A AGRICULTURE, MEDICINE ROHM AND HAAS COMPANY (US) 1998-05-19 — — US disclosed
WO-1997013758-A1 PYRIDAZINONES AS ENDOTHELIN-RECEPTOR ANTAGONISTS MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1997-04-17 — — WO disclosed
US-5552409-A PHYTOPATHOGENIC, RICE ROHM AND HAAS COMPANY (US) 1996-09-03 — — US disclosed
EP-0478195-A1 Dihydropyridazinones, pyridazinones and related compounds as fungicides ROHM AND HAAS COMPANY (US) 1992-04-01 — — EP disclosed
US-4397854-A INCREASE IN MYOCARDIAL CONTRACTILITY WARNER-LAMBERT COMPANY (US) 1983-08-09 — — US disclosed
US-4136184-A TRANQUILIZERS, ANTICONVULSANTS, MUSCLE RELAXANTS SANDOZ, INC. (US) 1979-01-23 — — US disclosed
US-4117130-A 6-PHENYL-1,2,4-TRIAZOLO(4,3-B)PYRIDAZINES AMERICAN CYANAMID COMPANY (US) 1978-09-26 — — US disclosed
US-4112095-A 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents AMERICAN CYANAMID COMPANY (US) 1978-09-05 — — US disclosed
US-4092311-A Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates AMERICAN CYANAMID COMPANY (US) 1978-05-30 — — US disclosed
US-4055644-A CNS DEPRESSANTS SANDOZ, INC. (US) 1977-10-25 — — US disclosed
US-3931176-A CNS DEPRESSANT SANDOZ INC. (US) 1976-01-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182452-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER PDE3A, PDE3B, PDE5A SMN1; SMN2 3303/4885KCNH2 2090/4885MAPT 4581/4885
US-20200247783-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER PDE3B, PDE3A, PDE5A SMN1; SMN2 3985/4885KCNH2 1930/4885MAPT 4097/4885
US-11897867-B2 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer PDE3B, PDE3A, PDE5A SMN1; SMN2 3985/4885KCNH2 1930/4885MAPT 4097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.